Condition
Asymptomatic COVID-19
Total Trials
4
Recruiting
0
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Completed3
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05787444Completed
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Combo Test
NCT05040659Active Not Recruiting
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
NCT05398705Phase 2CompletedPrimary
Study of Oral High/Low-dose Cepharanthine Compared With Placebo in Non Hospitalized Adults With COVID-19
NCT05331976Completed
A Clinical Evaluation of Proof Diagnostics Test System Including the Proof Diagnostics Reader and COVID-19 Test
Showing all 4 trials